"Trojan Horse" Delivery System Attacks Cancer Cells From Inside

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry
Article Date: 28 Jul 2010 - 1:00 PDT

email to a friend   printer friendly   opinions  

Combining nature and Greek mythology, researchers at the Technion-Israel Institute of Technology have developed a tiny "Trojan Horse" system for delivering cancer-fighting drugs. With this system, the drugs are delivered only once they are inside the cancerous cells, so there is no damage to the healthy cells in the surrounding area.

The researchers created the system by attaching folic acid and an anticancer drug to an extract from the coniferous Larix (Larch) tree, which are among the dominant plants in the immense boreal forests of Russia and Canada.

"We were looking for a natural polymer that would be highly soluble in water, and found it in a polysaccharide known as arabinogalactan, which is extracted from the Larix," explains lead researcher Dr. Yoav Livney, of the Technion Faculty of Biology and Food Engineering and the Technion Russell Berrie Nanotechnology Institute.

Certain cancerous cells produce between 10 to 100 times more folate receptors than healthy cells. These receptors bind folic acid, which is required by cancer cells to grow and divide rapidly. As a result, the researchers used folic acid as the bait for targeting cancer cells.

Once the folic acid is bound to the receptor, a process is triggered whereby the cell membrane folds inward, creating a "bubble" (organelle) called an endosome. These endosomes fuse with other naturally-occurring organelles termed lysosomes, which contain enzymes that serve as the digestive system of the cell.

Dr. Livney and Prof. Yehuda Assaraf (of the Technion Faculty of Biology and head of the Fred Wiszkowski Cancer Research Lab) designed the novel drug delivery system by attaching an antitumor drug to the polysaccharide by a small fragment of a protein (a peptide), which is digested by the enzymes present in the lysosome. As a result, the anticancer drug is released only in the lysosome, because there are no equivalent enzymes in the blood that can break down this specific peptide.

The development is expected to be especially efficient against ovarian, kidney and uterine cancer, which are characterized by high production of folic acid receptors. In the future, this novel chemotherapeutic delivery system will be able to simultaneously deliver several anti-cancer drugs, whose tailor-made synergistic combination would lead to an optimal eradication of malignant cells of a specific cancer type, in individual cancer patients.

Also contributing to this research was Prof. Avi Domb, of the School of Pharmacy at Hebrew University of Jerusalem.

Source:
American Technion Society

• Additional
• References
• Citations